Cycling Quiescence in Temozolomide Resistant Glioblastoma Cells Is Partly Explained by MicroRNA-93 and -193-Mediated Decrease of Cyclin D

Overview

Journal Front Pharmacol

Date 2019 Mar 12

PMID 30853911

Citations 15

Authors

Jessian L Munoz

Nykia D Walker

Satvik Mareedu

Sri Harika Pamarthi

Garima Sinha

Steven J Greco

Pranela Rameshwar

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme (GBM) is a fatal malignancy of the central nervous system, commonly associated with chemoresistance. The alkylating agent Temozolomide (TMZ) is the front-line chemotherapeutic agent and has undergone intense studies on resistance. These studies reported on mismatch repair gene upregulation, ABC-targeted drug efflux, and cell cycle alterations. The mechanism by which TMZ induces cell cycle arrest has not been well-established. TMZ-resistant GBM cells have been linked to microRNA (miRNA) and exosomes. A cell cycle miRNA array identified distinct miRNAs only in exosomes from TMZ-resistant GBM cell lines and primary spheres. We narrowed the miRs to miR-93 and -193 and showed in computational analyses that they could target Cyclin D1. Since Cyclin D1 is a major regulator of cell cycle progression, we performed cause-effect studies and showed a blunting effects of miR-93 and -193 in Cyclin D1 expression. These two miRs also decreased cell cycling quiescence and induced resistance to TMZ. Taken together, our data provide a mechanism by which GBM cells can exhibit TMZ-induced resistance through miRNA targeting of Cyclin D1. The data provide a number of therapeutic approaches to reverse chemoresistance at the miRNA, exosomal and cell cycle points.

Citing Articles

Exploring the roles and clinical potential of exosome-derived non-coding RNAs in glioma.

Jin P, Bai X IBRO Neurosci Rep. 2025; 18:323-337.

PMID: 40034544 PMC: 11872630. DOI: 10.1016/j.ibneur.2025.01.015.

Extracellular Vesicles as Mediators and Potential Targets in Combating Cancer Drug Resistance.

Zhang H, Wu B, Wang Y, Du H, Fang L Molecules. 2025; 30(3).

PMID: 39942602 PMC: 11819960. DOI: 10.3390/molecules30030498.

Epigenetic Downregulation of Hsa-miR-193b-3p Increases Cyclin D1 Expression Level and Cell Proliferation in Human Meningiomas.

Kober P, Mossakowska B, Rusetska N, Baluszek S, Grecka E, Konopinski R Int J Mol Sci. 2023; 24(17).

PMID: 37686289 PMC: 10487813. DOI: 10.3390/ijms241713483.

Forging New Therapeutic Targets: Efforts of Tumor Derived Exosomes to Prepare the Pre-Metastatic Niche for Cancer Cell Dissemination and Dormancy.

Bhatia R, Chang J, Munoz J, Walker N Biomedicines. 2023; 11(6).

PMID: 37371709 PMC: 10295689. DOI: 10.3390/biomedicines11061614.

A rationally identified panel of microRNAs targets multiple oncogenic pathways to enhance chemotherapeutic effects in glioblastoma models.

Sadeghipour N, Kumar S, Massoud T, Paulmurugan R Sci Rep. 2022; 12(1):12017.

PMID: 35835978 PMC: 9283442. DOI: 10.1038/s41598-022-16219-x.

References

Thery C, Zitvogel L, Amigorena S . Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-79. DOI: 10.1038/nri855. View

Freemantle S, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D . Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem. 2007; 102(4):869-77. DOI: 10.1002/jcb.21519. View

Louis D . Molecular pathology of malignant gliomas. Annu Rev Pathol. 2007; 1:97-117. DOI: 10.1146/annurev.pathol.1.110304.100043. View

Chen J, Feilotter H, Pare G, Zhang X, Pemberton J, Garady C . MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol. 2010; 176(5):2520-9. PMC: 2861116. DOI: 10.2353/ajpath.2010.091061. View

Jiang G, Wei Z, Pei D, Xin Y, Liu Y, Zheng J . A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. Biochem Biophys Res Commun. 2011; 406(3):311-4. DOI: 10.1016/j.bbrc.2011.02.042. View

Lim P, Bliss S, Patel S, Taborga M, Dave M, Gregory L . Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 2011; 71(5):1550-60. DOI: 10.1158/0008-5472.CAN-10-2372. View

Naydenov E, Tzekov C, Minkin K, Nachev S, Romansky K, Bussarsky V . Long-term survival with primary glioblastoma multiforme: a clinical study in bulgarian patients. Case Rep Oncol. 2011; 4(1):1-11. PMC: 3085065. DOI: 10.1159/000323432. View

Yu X, Zou J, Bao Z, Dong J . miR-93 suppresses proliferation and colony formation of human colon cancer stem cells. World J Gastroenterol. 2011; 17(42):4711-7. PMC: 3233678. DOI: 10.3748/wjg.v17.i42.4711. View

Pant S, Hilton H, Burczynski M . The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol. 2012; 83(11):1484-94. PMC: 7110994. DOI: 10.1016/j.bcp.2011.12.037. View

10.

Fu X, Tian J, Zhang L, Chen Y, Hao Q . Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett. 2012; 586(9):1279-86. DOI: 10.1016/j.febslet.2012.03.006. View

11.

Johannessen T, Bjerkvig R . Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther. 2012; 12(5):635-42. DOI: 10.1586/era.12.37. View

12.

Spinelli G, Miele E, Lo Russo G, Miscusi M, Codacci-Pisanelli G, Petrozza V . Chemotherapy and target therapy in the management of adult high- grade gliomas. Curr Cancer Drug Targets. 2012; 12(8):1016-31. DOI: 10.2174/156800912803251207. View

13.

Park J, Munoz J, Won B, Bliss S, Greco S, Patel S . Exogenous CXCL12 activates protein kinase C to phosphorylate connexin 43 for gap junctional intercellular communication among confluent breast cancer cells. Cancer Lett. 2012; 331(1):84-91. DOI: 10.1016/j.canlet.2012.12.007. View

14.

Di Leva G, Garofalo M, Croce C . MicroRNAs in cancer. Annu Rev Pathol. 2013; 9:287-314. PMC: 4009396. DOI: 10.1146/annurev-pathol-012513-104715. View

15.

Munoz J, Bliss S, Greco S, Ramkissoon S, Ligon K, Rameshwar P . Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity. Mol Ther Nucleic Acids. 2013; 2:e126. PMC: 4027430. DOI: 10.1038/mtna.2013.60. View

16.

Beach A, Zhang H, Ratajczak M, Kakar S . Exosomes: an overview of biogenesis, composition and role in ovarian cancer. J Ovarian Res. 2014; 7:14. PMC: 3932023. DOI: 10.1186/1757-2215-7-14. View

17.

Sen R, Ghosal S, Das S, Balti S, Chakrabarti J . Competing endogenous RNA: the key to posttranscriptional regulation. ScientificWorldJournal. 2014; 2014:896206. PMC: 3929601. DOI: 10.1155/2014/896206. View

18.

Munoz J, Rodriguez-Cruz V, Greco S, Ramkissoon S, Ligon K, Rameshwar P . Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. Cell Death Dis. 2014; 5:e1145. PMC: 3973225. DOI: 10.1038/cddis.2014.111. View

19.

Tezcan G, Tunca B, Bekar A, Preusser M, Berghoff A, Egeli U . microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. Cell Mol Neurobiol. 2014; 34(5):679-92. PMC: 11488951. DOI: 10.1007/s10571-014-0050-0. View

20.

Hiddingh L, Raktoe R, Jeuken J, Hulleman E, Noske D, Kaspers G . Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis. Sci Rep. 2014; 4:5260. PMC: 4052714. DOI: 10.1038/srep05260. View